SCHEMBL20203531

SCHEMBL20203531

CC(C)c1ccc2c(n1)CCN(C(=O)[C@H]1CCNC1)C2

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 4/20 0.41
TLR8 Q9NR97 4/20 0.41
TLR7 Q9NYK1 4/20 0.41
GABRG2 P18507 4/20 0.38
GABRB3 P28472 4/20 0.38
GABRA5 P31644 4/20 0.38
KCNH2 Q12809 2/20 0.37
HSP90AA1 P07900 5/20 0.37
CDK4 P11802 2/20 0.37
KEAP1 Q14145 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNE1 P24864 1/20 0.37
HSP90B1 P14625 1/20 0.37
HDAC6 Q9UBN7 2/20 0.36
GRM5 P41594 1/20 0.36
PARP1 P09874 1/20 0.35
CDK2 P24941 1/20 0.35
CDK6 Q00534 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23733451 0.94 KEAP1 (0.40) TLR9TLR8TLR7GABRG2GABRB3
SCHEMBL20203431 0.93 KEAP1 (0.41) TLR9TLR8TLR7GABRG2GABRB3
SCHEMBL23733465 0.85 GABRG2 (0.41) TLR9TLR8TLR7GABRG2GABRB3
SCHEMBL20203457 0.84 GRM5 (0.49) GABRG2GABRB3GABRA5KCNH2HSP90AA1
SCHEMBL20203569 0.83 CDK1 (0.40) TLR9TLR8TLR7GABRG2GABRB3
SCHEMBL20203565 0.82 GABRG2 (0.39) GABRG2GABRB3GABRA5HSP90AA1HSP90B1
SCHEMBL20203643 0.82 HSP90AA1 (0.40) GABRG2GABRB3GABRA5KCNH2HSP90AA1
SCHEMBL20203597 0.81 GRM5 (0.47) GABRG2GABRB3GABRA5KCNH2HSP90AA1
SCHEMBL20203598 0.81 GRM5 (0.47) GABRG2GABRB3GABRA5KCNH2HSP90AA1
SCHEMBL23733474 0.80 CDK1 (0.45) HSP90AA1CDK4CDK1HSP90B1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 TLR9 1479/4885TLR8 2089/4885TLR7 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.